Clinical Trials Logo

Clinical Trial Summary

As the incidence of colorectal cancer (CRC) has been rapidly rising in Asian countries, more and more screening colonoscopies are now being performed for prevention or early detection of this fatal disease. Complete colonoscopy as indicated by caecal intubation is essential to make it a reliable screening tool for colorectal cancer or polyps. Cecal intubation rate is highly variable and dependent on individual experience. Colonic looping is the commonest cause of incomplete colonoscopy. Magnetic endoscope imaging (MEI) is a non-radiological imaging technique to provide real time, three-dimensional image and position of the colonoscope during the procedure. It may facilitate straightening of colonic loops and hence cecal intubation.

The investigators aim to evaluate the benefit of MEI in term of cecal intubation rate across endoscopists of all levels of experience by making use of the newly developed Endoscopy Position Detecting Unit (UPD-3)by Olympus Optical Co, Ltd, Japan.

The investigators propose to conduct a prospective randomized controlled trial to compare the caecal intubation rate of colonoscopy being performed with and without UPD-3 guidance. Colonoscopies performed by endoscopists with different level of experience will be randomized to UPD-3 guided group or conventional group (no UPD-3 guidance). Patient controlled sedation (PCS) containing propofol and alfentanil will be given to all patients. The investigators hypothesize that UPD-3 guided colonoscopy is associated with high caecal intubation rate (complete colonoscopy), shorter time to caecum, less patient pain and lower sedative medication requirement. A high caecal intubation rate facilitates a reliable colonoscopy screening. Decreased colonic looping and shorter time to caecum may reduce patient discomfort during the procedure. It may also facilitate learning and acquiring the skill of colonoscopy in trainees.


Clinical Trial Description

Hypothesis UPD guided colonoscopy improves cecal intubation rate.

Methods

Trial design This is a prospective randomized controlled trial comparing the cecal intubation rate of colonoscopy being performed with and without UPD guidance by endoscopists of different levels of experience. The trial will be conducted in the Endoscopy Unit of a university affiliated hospital.

Patients who will have elective colonoscopy in the Endoscopy Unit during the study period, and meet the following inclusion criteria are recruited. The colonoscopy will be done by 6 dedicated endoscopists with different levels of experience in performing colonoscopy.

Interventions

UPD-3 and the specific colonoscope with an in-built magnetic imaging facility (Olympus Optical Co, Ltd, Japan) will be used in all examinations. A mobile sensor will be attached to the assistant's hand, so that the hand position in relation to the colonoscope could be shown in the imager screen.

Patient controlled sedation (PCS) will be given to all patients. It is delivered by means of Graseby 3300 PCA pump (Graseby Medical Ltd), using a mixture of propofol (200mg in 20ml) and alfentanil (0.5mg in 1ml) in a 25-ml syringe. The drugs will be delivered in response to pressure on a hand-held button controlled by the patient. Each bolus (0.5ml) delivers 4.8mg propofol and 12microgram alfentanil. No loading dose was used and the lock-out time of the PCA machine was set at zero. All patients will be instructed in the use of the hand-held button before colonoscopy. Nasal oxygen (2l/min) will be given to all patients, and oxygen saturation and blood pressure will be continuously monitored throughout the procedure.

The procedure will be randomized to either with the colonoscopist viewing the imager screen or not.

UPD guided group: Both the colonoscopist and assistant will be viewing the imager screen during the whole procedure. Information about colonoscopy looping will interpreted and documented by the colonoscopist. Anterior-position view is the standard reference. When abdominal compression is required, the assistant nurse should have the hand held probe attached, such that abdominal compression is guided by the image.

Conventional group (non- UPD guided): The imager screen will be turned to the other side such that both the colonoscopist and assistant is blind to UPD images. When the colonoscopist encountered looping as defined by paradoxical movement of the tip or disproportionate advancement in endoscopic view to the shaft insertion, the colonoscopist is requested to estimate the type of loop formed. The images will be captured for later interpretation.

The primary outcome is cecal intubation rate. Cecal intubation is defined as visualization of appendix orifice and ileocaecal valve, procedure started by a trainee and taken over by supervisor before caecal intubation is regarded as incomplete.

Sample size

The cecal intubation rate could be increased by at least 11% for trainee in a randomized trial by Shah [14] and 16% for trainee and experienced endoscopist in another trial [15]. Since the overall cecal intubation rate in our Endoscopy unit without UPD guide is at least 90% already, the investigators expect a modest benefit from UPD guidance. Assume a difference of 5% in caecal intubation rate (from 90% in conventional group to 95% in the UPD guided group) with a power of 80% and a type I error of 5%, 2 sided analysis, 435 patients will be needed in each group. Thus a sample size of 870 patients is required.

Randomization

Informed consent will be obtained before colonoscopy in the Endoscopy Unit, if the patient fulfils the inclusion criteria. Block randomization will be done on a 1:1 basis, to ensure equal number of UPD guided or conventional colonoscopies are done by each endoscopist.

A sealed non-opaque envelope (produced according to the computer generated random sequence) will be opened to determine the appropriate limb of entry before scope insertion.

It is not possible to blind the study.

Statistical analysis

The data will be analyzed according to the intention-to-treat principle. The chi-squared test (or Fisher's exact test when appropriate), Student's t-test, and Mann-Whitney U test will be used to compare categorical, parametric, and non-parametric data, respectively. A P value <0.05 is considered statistically significant.

Planned interim analysis will be conducted after recruiting 50% of patients.

Data collection Data will be collected by the in-charged endoscopist and assistant after each procedure in a standardized data sheet.

Accrual rate It is expected that about 20 cases per week will be recruited for randomization. The study could be finished in around 1 year time. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


NCT number NCT01434199
Study type Interventional
Source Chinese University of Hong Kong
Contact Sophie SF Hon, MD
Phone 852-2632 1495
Email honsf@surgery.cuhk.edu.hk
Status Recruiting
Phase Phase 3
Start date July 2011
Completion date July 2012

See also
  Status Clinical Trial Phase
Recruiting NCT04552093 - Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT) Phase 2/Phase 3
Completed NCT04192565 - A Prospective Investigation of the ColubrisMX ELS System N/A
Completed NCT05178745 - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Recruiting NCT03561350 - Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing
Recruiting NCT06128798 - Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery. N/A
Recruiting NCT03602677 - Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage N/A
Completed NCT03631407 - Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) Phase 2
Withdrawn NCT04192929 - Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy N/A
Recruiting NCT03042091 - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Early Phase 1
Terminated NCT02842580 - De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02889679 - Underwater Resection of Non-pedunculated Colorectal Lesions N/A
Completed NCT02564835 - Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer N/A
Completed NCT02503696 - Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) N/A
Completed NCT02149108 - Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1) Phase 3
Completed NCT02599103 - The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects N/A
Completed NCT01719926 - Phase I Platinum Based Chemotherapy Plus Indomethacin Phase 1
Completed NCT01669109 - Hatha Yoga for Patients With Colorectal Cancer N/A
Recruiting NCT01428752 - Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer N/A
Completed NCT01978717 - General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer N/A
Completed NCT01877018 - Colorectal Cancer Screening in Primary Care N/A